Vascular

Less than six weeks after making the announcement that it was to acquire AccessClosure, Cardinal Health has now seen the deal completed, marking the start of its Interventional Vascular journey. The $320 million acquisition was an all-cash transaction.

Veryan Medical’s MIMICS study of its 3D helical vascular stent has reached the two year point and will see results presented at the 15th Annual New Cardiovascular Horizons (NCVH) Conference taking place between May 28th and 30th in New Orleans.

Argon Medical Devices, Inc. unveiled its CLEANERXT™ Rotational Thrombectomy System at the recent 2014 Society of Interventional Radiology meeting in San Diego. Now the company tells us it has begun marketing the system, which is a new addition to the CLEANER family of dialysis products.

ROX Medical has completed enrollment in its CONTROL-HTN trial, an international multi center, prospective, randomized, controlled, blinded endpoint trial of the ROX Coupler for the treatment of arterial hypertension.

Covidien plc has notified customers of a voluntary recall to address an issue with certain lots of its Pipeline™ Embolization Device and Alligator™ Retrieval Device where the polytetrafluoroethylene (PTFE) coating applied to the delivery wire could delaminate and detach from the devices.

Cardinal Health has announced an agreement to acquire privately held extravascular closure device, AccessClosure, Inc., for $320 million, in a deal that is expected to close by early June 2014.

Ablative Solutions, Inc., has received U.S. FDA 510(k) clearance for its Peregrine System™ Infusion Catheter. The system uses a unique, patent-pending technology to deliver diagnostic and therapeutic agents directly to the perivascular layer that surrounds blood vessels.

AccessClosure Inc., has commercially launched its Mynx Ace Vascular Closure Device at ACC 2014. The company says the device is a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites.

Abbott’s Supera® Peripheral Stent System has received U.S. FDA approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). PAD occurs when fat and cholesterol buildup causes arteries outside of the heart to narrow, which reduces blood flow to parts of the body, most commonly the legs. The disease affects 12 to 20 percent of Americans age 65 or older and can cause leg pain, in addition to increasing the risk of heart attack or stroke.

Pretty complicated looking deal, but at the end of it CryoLife comes out with a nice adjunct to its vascular access graft portfolio.

TriReme Medical LLC, tells us that the first three patients have been enrolled in a clinical study of its funkily named Chocolate® PTA drug-coated balloon.

Newly FDA cleared Restated Indications for Use modify the weight range for Teleflex’s EZ-IO® 25 mm Needle Set for patients 3 kg or over.

BioCardia®, Inc. has gained CE Mark approval for its Morph AccessPro™ Steerable Introducer, designed for easier navigation through the vasculature during delivery of biotherapeutics and medical devices.

Scottish vascular graft company Vascutek has announced the return to market of its Anaconda™ Bifurcate Body Stent Graft System. The system has been out of circulation since October 2013.

CSI’s new Diamondback Peripheral 60cm systems are available in two crown designs, the 1.25mm Micro Crown, and the 1.25mm Solid Crown. Each device offers a shorter shaft length, a smaller profile and a more flexible shaft than their predecessors for improved ease of use.

Cook Medical has updated us with news that the first ten patients in its VIVO venous stent study have been treated with the Zilver Vena stent.